Researchers in Australia have found a way to wake up healthy genes that stay switched off in people living with Prader-Willi syndrome, a rare and complex genetic condition. The work, published on October 27, 2026, points toward a future treatment that tackles the underlying cause of the condition rather than only managing its symptoms.
Prader-Willi syndrome affects the brain and causes lifelong physical and developmental challenges. Around 400,000 people around the world live with the condition. Families often face a daily routine built around medication, specialist appointments and surgery, while the intense hunger that is a hallmark of the condition can create serious health risks.
The new study, led by researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, focuses on a protein called SMCHD1. In Prader-Willi syndrome, this protein helps keep certain genes silent, including genes that matter for brain function and development. By removing SMCHD1 in laboratory experiments, the team was able to lift that brake and restore activity in the dormant genes.
Key Takeaways
- WEHI researchers restored activity in healthy genes that are silenced in Prader-Willi syndrome by removing the protein SMCHD1.
- The gene activity returned in patient-derived cells and animal models without disrupting the rest of the body, according to the study team.
- The approach is still at an early research stage and is being developed toward potential new medicines, not yet a treatment patients can receive.
How the genetic brake works
SMCHD1 was first identified at WEHI in 2008, and the new findings build on almost two decades of follow-up research. The protein helps control which genes are active and which stay quiet. In Prader-Willi syndrome, that control system works against the patient: genes that should support development and brain function remain switched off, contributing to developmental delays, intellectual disability and an appetite that is difficult to control.
Current care for the condition usually treats one problem at a time. Medication, surgery and specialist support can help with individual symptoms, but they do not change the genetic mechanism behind them. That gap is why a root-cause approach has drawn so much attention from researchers and from families living with the condition.
For the new study, the team combined CRISPR gene-editing tools, stem-cell techniques and large-scale genomic analysis. They tracked what happened across thousands of genes when SMCHD1 was removed, and they paid close attention to the brain tissue most relevant to the condition. The result was a clear restoration of gene activity in the places where it had been lost.
The gene activity returned in patient-derived cells and animal models without disrupting the rest of the body, a result the researchers describe as a critical step toward future treatments.
Why safety mattered as much as the switch itself
Switching genes back on is only useful if it can be done without causing harm elsewhere. That question was central to the study. Lead researcher Marnie Blewitt, deputy director of WEHI and head of its epigenetics laboratory, said the team had long believed reactivation might be possible, but the safety question remained open until now.
The researchers report that restoring the dormant genes did not cause problems in other parts of the body in their experiments. That finding matters because any future treatment, especially one intended for babies and young children, would need to act precisely and leave the rest of the genome alone. It does not mean a medicine is ready, but it does remove one of the biggest obstacles in the path from laboratory discovery to clinical testing.
The work is now being advanced toward potential new medicines through Togglelux Therapeutics, a WEHI spinout company. That next phase will test whether the laboratory approach can be turned into a safe and practical therapy, a process that typically takes years and must pass rigorous clinical trials before any patient can benefit.
- SMCHD1 was discovered at WEHI in 2008 and has been studied for almost two decades.
- The study used CRISPR, stem-cell and genomic tools to track thousands of genes.
- Gene activity was restored in patient-derived cells and animal models.
- Development toward potential medicines is under way through Togglelux Therapeutics.
What this means for families
For families, the significance of the discovery is easier to grasp in everyday terms than in laboratory language. Prader-Willi syndrome shapes almost every part of daily life, from food and sleep to schooling and medical care. The Prader-Willi Research Foundation Australia has described the condition as one of the most complex a family can face, with children and adults navigating a world full of food they cannot eat while feeling a powerful drive to eat it.
A treatment that addresses the root cause could, in time, ease that burden in a way symptom-by-symptom care cannot. Researchers and patient advocates are careful to keep that hope in proportion: the study is early-stage science, and families should not expect a new treatment to appear quickly. Still, the step from a long-standing theory to demonstrated gene reactivation in relevant cells and animal models is the kind of result that changes what researchers believe is possible.
The finding also sits within a wider wave of genetics and health research, from new quantum research tools to new safeguards around advanced science and recent progress in cancer drug combinations. In each case, the distance between a laboratory result and a real-world benefit is long, but the direction of travel is set by careful, peer-reviewed work like this study, published in the journal Science Advances.
What to Watch Next
What to watch next is whether the SMCHD1 approach can move from laboratory models toward a medicine that is safe enough for clinical testing, and whether that medicine can restore gene activity in people without disrupting the rest of the body. Researchers will also be watching how the work through Togglelux Therapeutics develops, and how long the path to any future treatment proves to be. For now, the study stands as an early but important step: healthy genes that were silent in Prader-Willi syndrome can be switched back on, and that discovery gives families and researchers a clearer reason for hope.